The FDA on March 3, 2023, approved VERZENIO® with endocrine therapy (Tamoxifen or an Aromatase Inhibitor) for the adjuvant treatment of adult patients with Hormone Receptor (HR)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. VERZENIO® is a product of Eli Lilly and Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
